Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary

Akebia Therapeutics®, Inc. (Nasdaq: AKBA) plans to report Q4 and full year 2023 financial results on March 14, 2024. The company will not host a conference call due to the proximity to the PDUFA target action date for vadadustat, a potential treatment for anemia in patients on dialysis.

CAMBRIDGE, Mass., March 11, 2024 /PRNewswire/ -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report fourth quarter and full year 2023 financial results on March 14, 2024. Akebia will not host a conference call due to the proximity to the anticipated March 27, 2024 Prescription Drug User Fee Act (PDUFA) target action date for vadadustat, which is under review by the U.S. Food and Drug Administration as a treatment for anemia due to chronic kidney disease in adult patients on dialysis.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-report-fourth-quarter-and-full-year-2023-financial-results-302085663.html

SOURCE Akebia Therapeutics, Inc.

FAQ

When will Akebia Therapeutics report its Q4 and full year 2023 financial results?

Akebia Therapeutics will report its Q4 and full year 2023 financial results on March 14, 2024.

What is the PDUFA target action date for vadadustat?

The PDUFA target action date for vadadustat is anticipated to be on March 27, 2024.

What is vadadustat being reviewed for by the U.S. Food and Drug Administration?

Vadadustat is under review by the U.S. FDA as a treatment for anemia due to chronic kidney disease in adult patients on dialysis.

Why is Akebia Therapeutics not hosting a conference call for the financial results announcement?

Akebia Therapeutics is not hosting a conference call due to the proximity to the PDUFA target action date for vadadustat.